Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet?

Abstract

It has been nearly 20 years since the first Phase I clinical trial of a live-attenuated bacterial vaccine was created by recombinant DNA methods, opening the door to the use of these organisms as mucosal delivery vehicles for passenger antigens. Over this time, a number of animal studies have indicated the feasibility of this approach. These include studies… (More)

Topics

Cite this paper

@article{Lewis2007LiveattenuatedSA, title={Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet?}, author={George K. Lewis}, journal={Expert review of vaccines}, year={2007}, volume={6 3}, pages={431-40} }